3-[4-(4-trifluoromethyl-phenyl)-oxazol-2-yl]-propan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[4-(4-trifluoromethyl-phenyl)-oxazol-2-yl]-propan-1-ol
• 英文别名: 3-[4-[4-(trifluoromethyl)phenyl]-1,3-oxazol-2-yl]propan-1-ol
• 化学式: C₁₃H₁₂F₃NO₂
• 分子量: 271.239
• InChiKey: GLNNLEHNOBWCPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-[4-(4-trifluoromethyl-phenyl)-oxazol-2-yl]-propan-1-ol 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 potassium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 四氯化碳 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.5h， 生成 3-(5-bromo-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)-3-(3-carbamoyl-2,4-difluorophenoxy)propyl acetate
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ

  摘要：

  The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.002
• 作为产物：
  描述：

  2-溴-4'-(三氟甲基)苯乙酮 在 sodium tetrahydroborate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 3-[4-(4-trifluoromethyl-phenyl)-oxazol-2-yl]-propan-1-ol
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ

  摘要：

  The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.002

文献信息

• COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
  申请人：Epple Robert

  公开号：US20090192203A1

  公开（公告）日：2009-07-30

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

  本发明提供了化合物，包括这些化合物的制药组合物以及使用这些化合物治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族活性相关的疾病或疾病的方法。
• WO2007/56366
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES EN TANT QUE MODULATEURS DES PPAR
  申请人：IRM LLC

  公开号：WO2007056366A2

  公开（公告）日：2007-05-18

  [EN] The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.
  [FR] L'invention concerne des composés, des compositions pharmaceutiques comprenant lesdits composés ainsi que des procédés d'utilisation desdits composés dans le traitement ou la prévention de maladies ou de troubles associés à l'activité des familles de récepteurs activés de la prolifération des peroxysomes (PPAR).